BTG has raised £106.3 M (US$161 M) in a private placement to help fund the acquisitions of US-based Ekos and the Targeted Therapies division of Nordion as it strives to become a leading player in the interventional medicine market. Ekos’ EkoSonic® Endovascular System, an interventional product for the treatment of blood clots, generated sales of US$28 M in 2012. Nordion’s TheraSphere® comprises radioactive glass beads for the targeted treatment of inoperable primary and metastatic liver cancer. The acquisitions will complement BTG’s existing interventional medicine business, which it gained through its 2010 purchase of Biocompatibles.